AUTHOR SUMMARY
Gene expression in cells is controlled by the recruitment of specific proteins to so-called promoter regions of the genome that coordinate the synthesis of mRNA from DNA, a process called transcription. Understanding transcriptional regulation is challenging, because protein occupancy on a gene's promoter is dynamic, complex, and variable between cells. Here, we exploited cell to cell heterogeneities in transcription to uncover a specific pattern of regulation between two transcription factor proteins, called Forkhead box O (FOXO) and Runt-related transcription factor 1 (RUNX1), which act as gene switches. In breast epithelial cells, FOXO and RUNX1 regulate transcription such that one or the other protein, but not both together, can act as a tumor suppressor. This study provides insight into the tumor-suppressive functions of proteins that modulate gene expression.
To examine cell to cell differences in mRNA expression, we used a recently developed technique called stochastic profiling (1). This method examines the statistical fluctuations of gene expression measurements collected from random samplings of 10 cells (Fig. P1A) . Among repeated 10-cell measurements, genes with levels that fluctuate more than expected are predicted to be heterogeneously expressed. After extracting candidate heterogeneities, we can cluster genes based on their pattern of sampling fluctuations to identify heterogeneous transcriptional programs.
In our first application of stochastic profiling (1), we examined transcriptional heterogeneities among matrix-attached cells in a 3D culture model of breast epithelial cells. One candidate that we identified and provisionally validated was FOXO1. Because FOXO1 is itself a transcription factor that could lead to secondary heterogeneities in mRNA expression, we began our study here with a focused panel of 15 reported FOXO target genes that are expressed during 3D cell culture (Fig. P1A) . After measuring the 10-cell sampling fluctuations of the panel, we discovered that most FOXO genes fell into one of two groups. Both groups were found to be heterogeneous, but their pattern of expression among single cells was markedly different.
How could the regulation of the two FOXO groups differ? A simple explanation was that one of the groups was under control of a second class of transcription factors. Using bioinformatics, we identified a shared promoter sequence that distinguished one group from the other. This shared sequence contained a DNA binding site for the RUNX family of transcription factors. The breast epithelial cells used for 3D culture express RUNX1 and RUNX2, but RUNX1 mRNA was expressed at >15-fold higher levels than RUNX2, suggesting that RUNX1 was the dominant isoform. Furthermore, we found that RUNX1 promoter binding was strong in one FOXO group but not the other, which is in agreement with the bioinformatics-based prediction.
To test whether RUNX1-and FOXO-mediated gene expression were functionally coupled, we looked for phenotypes that emerged in 3D culture when RUNX1, FOXO, or both were perturbed. We found that RUNX1 knockdown caused cells to proliferate for longer in 3D culture and that disruption of FOXO function blocked the sustained proliferation. This genetic interaction was surprising, because FOXO target genes are often antiproliferative. To solve this puzzle, we examined the levels of reactive oxygen species during morphogenesis, because FOXOs have been implicated in protecting cells from oxidative stress (2). We found that FOXO disruption primed cells for substantial increases in reactive oxygen species when RUNX1 was knocked down. The resulting oxidative catastrophe caused a secondary proliferation arrest that restored normal 3D morphology, thereby explaining the observed genetic interaction between RUNX1 and FOXOs (Fig. P1B) .
Finally, we asked whether the FOXO-RUNX1 dependencies seen in 3D culture were recapitulated in clinical breast cancer specimens. Both RUNX1 and FOXOs are recognized tumor suppressors, but our results predicted that reduction or loss of RUNX1 expression would require FOXO activity to enable cells to withstand the resulting oxidative stress. In a retrospective study of hormone-negative tumors that lacked amplification of the human epidermal growth factor receptor 2 oncogene, we found that tumors with the lowest RUNX1 expression had among the highest levels of FOXO1 expression. This negative correlation raises the possibility that the FOXO and RUNX1 transcriptional programs may intersect in vivo like we observed in 3D culture.
Our work in breast epithelial cells reveals a functionally important cross-talk between two recognized tumor suppressors that have largely been studied in other tissue contexts. FOXO-RUNX1 cross-talk was uncovered by using stochastic profiling to observe correlated cell to cell fluctuations in mRNA expression. The study illustrates how in-depth, quantitative observations of this kind can help generate testable hypotheses. It remains unclear what upstream signals give rise to the observed heterogeneities in FOXO expression and RUNX1 phosphorylation in 3D culture. Our hope is that continued profiling experiments combined with mechanistic studies will enumerate all of the important transcriptional states that matrix-attached cells occupy during 3D morphogenesis. With this information, we can begin to examine how the different subpopulations relate to one another and explore whether similar subpopulations exist in breast tumors.
